# A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

> **NCT02289482** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** GSK2838232 PIB (SDD)
- **DRUG:** GSK2838232 PIB (API)
- **DRUG:** Placebo
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT02289482
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-17
- **Primary completion:** 2015-03-10
- **Final completion:** 2015-03-10
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Study prematurely terminated due to safety concerns leading to clinical hold
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289482, "A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02289482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*